iSpecimen (ISPC) Cash & Equivalents (2020 - 2026)

iSpecimen's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 260.23% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 260.23% YoY), while the FY2025 annual figure was $6.9 million, up 266.31% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $2.8 million, down from $6.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $26.1 million in Q1 2022, with the low at $588775.0 in Q2 2025.
• The 5-year median for Cash & Equivalents is $2.7 million (2023), against an average of $7.0 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents sank 91.54% in 2023, then soared 266.31% in 2025.
• iSpecimen's Cash & Equivalents stood at $15.3 million in 2022, then plunged by 84.69% to $2.3 million in 2023, then retreated by 19.85% to $1.9 million in 2024, then jumped by 266.31% to $6.9 million in 2025, then sank by 59.03% to $2.8 million in 2026.
• Business Quant data shows ISPC's Cash & Equivalents at $2.8 million in Q1 2026, $6.9 million in Q4 2025, and $2.8 million in Q3 2025.